Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa M Eubanks

Showing results (41-50 of 57) with videos related to

Pageof 6
Sort By:
Journal of the American Chemical Society|October 15, 2009
Revisiting AI-2 quorum sensing inhibitors: direct comparison of alkyl-DPD analogues and a natural product fimbrolideColin A Lowery, Takumi Abe, Junguk Park, et al.
Journal of Medicinal Chemistry|February 27, 2016
Investigations of Enantiopure Nicotine Haptens Using an Adjuvanting Carrier in Anti-Nicotine Vaccine DevelopmentNicholas T Jacob, Jonathan W Lockner, Joel E Schlosburg, et al.
Bioorganic & Medicinal Chemistry Letters|August 3, 2020
Sulfonate-isosteric replacement examined within heroin-hapten vaccine designTyson F Belz, Paul T Bremer, Bin Zhou, et al.
ACS Infectious Diseases|July 25, 2022
Investigation of Salicylanilides as Botulinum Toxin AntagonistsEalin N Patel, Lucy Lin, Molly M Sneller, et al.
Journal of Medicinal Chemistry|October 17, 2013
Targeting botulinum A cellular toxicity: a prodrug approachPeter Silhár, Lisa M Eubanks, Hajime Seki, et al.
Bioorganic & Medicinal Chemistry Letters|June 11, 2017
Validation of onchocerciasis biomarker N-acetyltyramine-O-glucuronide (NATOG)Daniel Globisch, Lisa M Eubanks, Ryan J Shirey, et al.
Molecular Pharmaceutics|December 5, 2006
A molecular link between the active component of marijuana and Alzheimer's disease pathologyLisa M Eubanks, Claude J Rogers, Albert E Beuscher, et al.
ACS Infectious Diseases|October 28, 2024
Investigations of Thiosemicarbazides as Botulinum Toxin Active-Site Inhibitors: Enzyme, Cellular, and Rodent Intoxication StudiesEalin N Patel, Lucy Lin, Hyeri Park, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 10, 2010
Repositioning of an existing drug for the neglected tropical disease OnchocerciasisChristian Gloeckner, Amanda L Garner, Fana Mersha, et al.
Chemical Communications (Cambridge, England)|January 5, 2011
A cross-over inhibitor of the botulinum neurotoxin light chain B: a natural product implicating an exosite mechanism of actionNicholas T Salzameda, Lisa M Eubanks, Joseph S Zakhari, et al.
Pageof 6

Showing results (41-50 of 57) with videos related to

Sort By:
Pageof 6
Journal of the American Chemical Society|October 15, 2009
Revisiting AI-2 quorum sensing inhibitors: direct comparison of alkyl-DPD analogues and a natural product fimbrolideColin A Lowery, Takumi Abe, Junguk Park, et al.
Journal of Medicinal Chemistry|February 27, 2016
Investigations of Enantiopure Nicotine Haptens Using an Adjuvanting Carrier in Anti-Nicotine Vaccine DevelopmentNicholas T Jacob, Jonathan W Lockner, Joel E Schlosburg, et al.
Bioorganic & Medicinal Chemistry Letters|August 3, 2020
Sulfonate-isosteric replacement examined within heroin-hapten vaccine designTyson F Belz, Paul T Bremer, Bin Zhou, et al.
ACS Infectious Diseases|July 25, 2022
Investigation of Salicylanilides as Botulinum Toxin AntagonistsEalin N Patel, Lucy Lin, Molly M Sneller, et al.
Journal of Medicinal Chemistry|October 17, 2013
Targeting botulinum A cellular toxicity: a prodrug approachPeter Silhár, Lisa M Eubanks, Hajime Seki, et al.
Bioorganic & Medicinal Chemistry Letters|June 11, 2017
Validation of onchocerciasis biomarker N-acetyltyramine-O-glucuronide (NATOG)Daniel Globisch, Lisa M Eubanks, Ryan J Shirey, et al.
Molecular Pharmaceutics|December 5, 2006
A molecular link between the active component of marijuana and Alzheimer's disease pathologyLisa M Eubanks, Claude J Rogers, Albert E Beuscher, et al.
ACS Infectious Diseases|October 28, 2024
Investigations of Thiosemicarbazides as Botulinum Toxin Active-Site Inhibitors: Enzyme, Cellular, and Rodent Intoxication StudiesEalin N Patel, Lucy Lin, Hyeri Park, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 10, 2010
Repositioning of an existing drug for the neglected tropical disease OnchocerciasisChristian Gloeckner, Amanda L Garner, Fana Mersha, et al.
Chemical Communications (Cambridge, England)|January 5, 2011
A cross-over inhibitor of the botulinum neurotoxin light chain B: a natural product implicating an exosite mechanism of actionNicholas T Salzameda, Lisa M Eubanks, Joseph S Zakhari, et al.
Pageof 6